Education
About Us
Working with TipRanks
Follow Us
Collegium Pharmaceutical (COLL)
NASDAQ:COLL
COLL Stock Chart & Stats
$42.30
$3.70(12.70%)
At close: 4:00 PM EST
$42.30
$3.70(12.70%)
Day’s Range― - ―
52-Week Range$23.23 - $41.81
Previous CloseN/A
Volume233.62K
Average Volume (3M)373.09K
Market Cap
$1.13B
Enterprise ValueN/A
Total Cash (Recent Filing)$285.86M
Total Debt (Recent Filing)$813.99M
Price to Earnings (P/E)39.3
Beta0.43
Next Earnings
Feb 19, 2026EPS Estimate
2.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.25
Shares Outstanding31,502,127
10 Day Avg. Volume458,928
30 Day Avg. Volume373,091
Financial Highlights & Ratios
PEG Ratio0.40
Price to Book (P/B)4.04
Price to Sales (P/S)1.46
P/FCF Ratio4.55
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$45.50Price Target Upside7.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCOLL increased all of its 2025 guidance parameters, indicating confidence in future performance.
Product ExpansionAn update on business development endeavors to expand the product portfolio is anticipated, indicating potential growth opportunities.
ValuationThe company is considered undervalued based on its topline growth, profitability, and revenue durability.
Bears Say
Market CompetitionThere is a valuation disconnect in COLL's business driven largely by uncertainty around the potential for generic competition on these products.
Collegium Pharmaceutical News
COLL FAQ
What was Collegium Pharmaceutical’s price range in the past 12 months?
Collegium Pharmaceutical lowest stock price was $23.23 and its highest was $41.81 in the past 12 months.
What is Collegium Pharmaceutical’s market cap?
Collegium Pharmaceutical’s market cap is $1.13B.
When is Collegium Pharmaceutical’s upcoming earnings report date?
Collegium Pharmaceutical’s upcoming earnings report date is Feb 19, 2026 which is in 102 days.
How were Collegium Pharmaceutical’s earnings last quarter?
Collegium Pharmaceutical released its earnings results on Nov 06, 2025. The company reported $2.25 earnings per share for the quarter, beating the consensus estimate of $1.86 by $0.39.
Is Collegium Pharmaceutical overvalued?
According to Wall Street analysts Collegium Pharmaceutical’s price is currently Undervalued.
Does Collegium Pharmaceutical pay dividends?
Collegium Pharmaceutical does not currently pay dividends.
What is Collegium Pharmaceutical’s EPS estimate?
Collegium Pharmaceutical’s EPS estimate is 2.14.
How many shares outstanding does Collegium Pharmaceutical have?
Collegium Pharmaceutical has 31,502,127 shares outstanding.
What happened to Collegium Pharmaceutical’s price movement after its last earnings report?
Collegium Pharmaceutical reported an EPS of $2.25 in its last earnings report, beating expectations of $1.86. Following the earnings report the stock price went up 13.417%.
Which hedge fund is a major shareholder of Collegium Pharmaceutical?
Currently, no hedge funds are holding shares in COLL
Collegium Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$45.50 (7.57% Upside)
$45.50 (7.57% Upside)
Blogger Sentiment
Bullish
COLL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 5.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 7.4%
Last 30 Days ▲ 7.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.85%
12-Months-Change
Fundamentals
Return on Equity
22.96%
Trailing 12-Months
Asset Growth
51.19%
Trailing 12-Months
Company Description
Collegium Pharmaceutical
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative products for the treatment of pain and other central nervous system conditions. The company primarily operates in the pharmaceutical sector, with a core focus on abuse-deterrent formulations of medications to address the opioid crisis and improve patient safety. Collegium's flagship product is Xtampza ER, an extended-release oxycodone formulation designed to provide effective pain management while minimizing the potential for misuse.
COLL Company Deck
COLL Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Collegium Pharmaceuticals reported a strong quarter with record revenues and growth across key product lines, particularly Jornay PM and the pain portfolio. The company has shown effective strategic capital deployment and increased financial guidance for 2025, indicating confidence in continued growth. However, there are some concerns regarding gross to net variability and the delayed impact of sales force expansion.View all COLL earnings summariesCOLL Stock 12 Month Forecast
Average Price Target
$45.50
▲(7.57% Upside)
Technical Analysis
Avadel Pharmaceuticals
―
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Ownership Overview
13.39% Insiders
36.65% Mutual Funds
0.87% Other Institutional Investors
24.20% Public Companies and
Individual Investors